Rheumatoid Arthritis
Conditions
Keywords
Cardiac adaptations, Metabolic adaptations, High intensity interval training
Brief summary
The present study will investigative the physiological effects of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with rheumatoid arthritis. The investigators hypothesize that blockage of IL-6 receptors will decrease the cardiac and metabolic adaptations to exercise training compared to the inhibition of TNF. 80 patients will be included in a 12-week investigator blinded randomised exercise training intervention study.
Detailed description
80 patients with rheumatoid arthritis who are being treated with either interleukin-6 receptor blockers (IL-6Rb) or tumor necrosis factor inhibitors (TNFi) for a minimum of four months prior to enrollment will be recruited and undergo baseline testing, including examination, biochemistry, ECG, DXA, OGTT, pulmonary function, VO2max, echocardiography, cardiac MRI. After baseline testing, 40 patients in IL-6 receptor blocker treatment and 40 patients in TNF inhibitor treatment.will be randomly allocated into one group receiving standard of care (control group) or a group performing supervised high-intensity interval training three times a week over a period of 12 weeks. The randomization procedure involves a computer-generated block randomization schedule in a ratio of 1:1 stratified by sex by an independent person. Following the 12-week intervention period, all groups will complete a series of follow-up tests (as baseline testing).
Interventions
BEHAVIORALExercise
Supervised high-intensity interval training for 12 weeks three times per week. The supervision may be physical or online supervision
BEHAVIORALNo exercise
Control group, therefore no supervised exercise regime
Sponsors
Rigshospitalet, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age \>= 18 and \<70 years * Informed consent * Diagnosed RA based on the 2010 American College of Rheumatology/ EULAR criteria. In biological treatment with either IL-6rB og TNFi over four months prior to enrollment * Low RA disease activity, based on the Disease Activity Score-28 ESR for Rheumatoid Arthritis (DAS28) \<=3.2 * An electrocardiogram without features of left ventricular hypertrophy defined by the European Society of Cardiology * Females of childbearing potential have to use one or more of the following highly effective methods for contraception in order to be included: * Vasectomized partner * Bilateral tubal occlusion * Sexual abstinence * Intrauterine device * Hormonal contraception * Females who are considered to have no childbearing potential are * Bilateral tubal ligation * Bilateral oophorectomy * Complete hysterectomy * Postmenopausal defined as 12 months with no menses without an alternative medical cause
Exclusion criteria
* Health conditions that prevent participating in the exercise intervention determined by the Project Coordinator * Subjects who cannot undergo MRI scans (metallic implants or claustrophobia) * Corticosteroid use per os \> 10 mg/day within seven days of study enrollment * Intramuscular corticosteroid within 3 weeks of the study enrollment * Grade 2 hypertension (systolic BP \> 160 mmHg and/or diastolic BP \>100 mmHg) despite the use of antihypertensive drugs. * Pregnancy * Subjects with insulin dependent Diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in left ventricular mass | 12 weeks | measured by MRI scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Visceral adipose tissue mass | 12 weeks | measured by MRI scan |
| Stroke volume | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| Left ventricular and atrial end-diastolic volume | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| LVEF | 12 weeks | Functional cardiac parameters: measured by MRI scan and echocardiography |
| Global longitudinal strain | 12 weeks | Functional cardiac parameters: measured by MRI scan and echocardiography |
| E/A ratio | 12 weeks | Functional cardiac parameters: measured by MRI scan and echocardiography |
| E/é | 12 weeks | Functional cardiac parameters: measured by MRI scan and echocardiography |
| Left ventricular and atrial end-systolic volume | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| Left atrial volume index | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| Interventricular septum thickness | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| Left ventricular posterior wall thickness | 12 weeks | Structural cardiac parameter: measured by MRI scan and echocardiography |
| Aortic and pulmonary distensibility and pulse wave velocity | 12 weeks | Functional vascular parameter: measured by MRI |
| Subcutaneous, visceral and epicardial adipose tissue | 12 weeks | Measured by MRI and MR spectroscopy |
| Intramyocardial triglyceride content | 12 weeks | Measured by MRI and MR spectroscopy |
| Cardiorespiratory fitness | 12 weeks | Measured with an incremental VO2 protocol on exercise bike |
| RA disease specific outcomes 4 | 12 weeks | Change in Short Form 36 (SF-36) Health Survey Questionnaire A 8-scale score within 8 domains.All items are scored so that a high score defines a more favorable health state. |
| Whole body plethysmography | 12 weeks | Pulmonary function testing |
| Diffusion capacity | 12 weeks | Pulmonary function testing |
| Body composition | 12 weeks | Measured by a DXA scan |
| Oral glucose tolerance test | 12 weeks | 75g of glucose taken while fasting |
| Axial accelerometer-based physical activity monitors | 5 days in week 6 of the intervention/control | Free-living physical activity is measured using axial accelerometer-based physical activity monitors (AX3; Axivity, Newcastle upon Tyne, UK) for a 5-day period |
| Dietary intake | 3 days in the week 6 of intervention/control | Self reported intake of all foods and liquids |
| Blood sample | 12 weeks | Change in fasting total cholesterol, low-density lipoprotein (LDL)-cholesterol and high-density lipoprotein (HDL)-cholesterol (mmol/L). Following an overnight fast (10 hours), blood samples are collected and processed by a trained laboratory technician and analysed according to standard procedures. |
| RA disease specific outcomes 1 | 12 weeks | Change in measures of the international Core Outcome Set for rheumatoid arthritis : 66/68 tender and swollen joint count |
| RA disease specific outcomes 2 | 12 weeks | Change in visual analogue scale (VAS) pain, VAS physician global assessment, VAS patient global assessment The Visual Analogue Scale (VAS) is a self-report measure consisting simply of a 100 mm horixontal line with a statement at each end representing one extreme (0mm = nothing, 100mm = extreme) |
| RA disease specific outcomes 3 | 12 weeks | Change in Health Assessment Questionnaire (HAQ-DI) Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. |
| RA disease specific outcomes 5 | 12 weeks | Change in the composite Disease Activity Score-28 ESR for Rheumatoid Arthritis (DAS28). A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission |
| RA disease specific outcomes 6 | 12 weeks | Change in response criteria will be assessed according the clinical disease activity index (CDAI). The CDAI composite index quantifies disease activity in RA, by utilising four clinical parameters including tender and swollen joints and global assessment from both patient and assessor on a vasual analogue scale. CDAI interpretation score CDAI ≥ 22,1: High Activity CDAI \< 22,1 og ≥10,1: Moderate Activity CDAI \<10,0 og ≥ 2,9: Low Activity CDAI \<2,9: Remission |
| RA disease specific outcomes 7 | 12 weeks | Change in response criteria will be assessed according the American College of Rheumatology (ACR 20/50/70) response |
| RA disease specific outcomes 8 | 12 weeks | Change in response criteria will be assessed according the European League Against Rheumatism (EULAR none/good/moderate response) |
| Dynamic spirometry | 12 weeks | Pulmonary function testing |
Countries
Denmark
Outcome results
None listed